Has activating or gain of function mutations in most GIST tumors, often at exon 11, less often at exons 9 and 13 (Hum Pathol 2002;33:484)

Tyrosine kinase activity of c-kit in GIST and bcl-abl overexpression in CML are inhibited by imatinib mesylate (Gleevec, STI571), a tyrosine kinase inhibitor used to treat these diseases (Hum Pathol 2002;33:466)

This website is intended for pathologists and laboratory personnel, who understand that medical information is imperfect and must be interpreted using reasonable medical judgment. We are unable to respond to patient inquiries.